BeiGene
ONC
364.02
+1.24
+0.34%
BeiGene
US · ONC
#538 by market cap
Listed 2016
364.02
+1.24
+0.34%
Live - 5344 symbols - heartbeat 98s ago
· 2026-10-08 05:10
Pre-market
353.40
-2.92%
After-hours
364.16
+0.04%
Overnight
353.82
-2.80%
- Market cap
- 41.39B
- P/E (TTM)i
- 64.43
- P/Bi
- 8.00
- EPSi
- 2.53
- Div yieldi
- 0.00%
- 52W posi
- 84%
Reader sentiment
Are you bullish or bearish on ONC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.54, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +40.23% YoY
Margins
- Gross margin
- 87.49%
- Operating margin
- 8.37%
- Net margin
- 5.37%
Key ratios & quality
- Enterprise valuei
- 37.88B
- Altman Z-Scorei
- 6.54
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 198.22M | 428.21M | 308.87M | 1.18B | 1.42B | 245.88M | 3.81B | 5.34B |
| Gross profit | 169.52M | 357.02M | 238.22M | 1.01B | 1.13B | 2.08B | 3.22B | 4.67B |
| Selling & admin expenses | 195.39M | 388.25M | 600.18M | 990.12M | 1.28B | 1.51B | 1.83B | 2.08B |
| Research & development | 679.01M | 927.34M | 1.29B | 1.46B | 1.64B | 1.78B | 1.95B | 2.15B |
| Operating profit | -705.77M | -959.89M | -1.66B | -1.44B | -1.79B | -1.21B | -568.20M | 447.14M |
| Pretax profit | -689.83M | -943.59M | -1.62B | -1.44B | -1.96B | -825.84M | -533.00M | 416.85M |
| Tax | -15.80M | 6.99M | 10.40M | 19.23M | 42.78M | 55.87M | 111.79M | 129.92M |
| Net profit | -674.03M | -950.58M | -1.63B | -1.46B | -2.00B | -881.71M | -644.79M | 286.93M |
| Basic EPS | -12 | -16 | -20 | -16 | -19 | -8 | -6 | 3 |
| Diluted EPS | -12.09 | -15.86 | -19.50 | -15.73 | -19.37 | -8.45 | -6.11 | 2.47 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.12B | 1.32B | 1.41B | 1.50B | 1.51B | 1.71B |
| Gross profit | 952.28M | 1.15B | 1.22B | 1.36B | 1.35B | 1.53B |
| Selling & admin expenses | 459.29M | 537.91M | 529.00M | 555.29M | 555.10M | 593.21M |
| Research & development | 481.89M | 524.90M | 523.66M | 615.42M | 541.22M | 612.28M |
| Operating profit | 11.10M | 87.89M | 163.11M | 185.04M | 249.90M | 325.05M |
| Pretax profit | 20.90M | 99.55M | 147.16M | 149.24M | 259.22M | 312.46M |
| Tax | 19.63M | 5.23M | 22.32M | 82.74M | 31.86M | 75.45M |
| Net profit | 1.27M | 94.32M | 124.84M | 66.50M | 227.36M | 237.01M |
| Basic EPS | 0 | 1 | 1 | 1 | 2 | 2 |
| Diluted EPS | 0.00 | 0.78 | 1.04 | 0.52 | 1.95 | 2.08 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.94B | 1.17B | 4.96B | 7.61B | 5.21B | 4.20B | 3.99B | 6.23B |
| Cash & ST investments | 1.78B | 982.74M | 4.65B | 6.62B | 4.53B | 3.17B | 2.63B | 4.55B |
| Inventory | 16.24M | 28.55M | 89.29M | 242.63M | 282.35M | 416.12M | 494.99M | 608.23M |
| Total assets | 2.25B | 1.61B | 5.60B | 8.54B | 6.38B | 5.81B | 5.92B | 8.19B |
| Total current liabilities | 246.45M | 310.31M | 1.08B | 1.60B | 1.47B | 1.81B | 2.21B | 1.83B |
| Short-term debt | 8.73M | 10.81M | 348.91M | 449.49M | 353.01M | 710.32M | 869.11M | 77.99M |
| Long-term debt | 189.67M | 240.70M | 183.64M | 202.11M | 209.15M | 197.62M | 166.48M | 961.91M |
| Total liabilities | 496,037,000.00 | 633,934,000.00 | 1,731,514,000.00 | 2,402,962,000.00 | 1,995,935,000.00 | 2,267,948,000.00 | 2,588,688,000.00 | 3,827,379,000.00 |
| Total equity | 1.75B | 978.36M | 3.87B | 6.13B | 4.38B | 3.54B | 3.33B | 4.36B |
| Retained earnings | -1.01B | -1.96B | -3.55B | -5.08B | -7.08B | -7.96B | -8.61B | -8.32B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.90B | 4.31B | 5.66B | 6.23B | 6.60B | 7.22B |
| Cash & ST investments | 2.52B | 2.76B | 4.04B | 4.55B | 4.79B | 5.10B |
| Inventory | 494.66M | 502.87M | 531.69M | 608.23M | 681.59M | 732.60M |
| Total assets | 5.84B | 6.30B | 7.63B | 8.19B | 8.55B | 9.18B |
| Total current liabilities | 1.98B | 2.21B | 2.37B | 1.83B | 1.81B | 2.12B |
| Short-term debt | 781.77M | 825.64M | 829.03M | 77.99M | 136.72M | 212.85M |
| Long-term debt | 160.16M | 146.09M | 139.57M | 961.91M | 962.52M | 882.16M |
| Total liabilities | 2,342,013,000.00 | 2,527,919,000.00 | 3,503,260,000.00 | 3,827,379,000.00 | 3,793,177,000.00 | 4,001,617,000.00 |
| Total equity | 3.50B | 3.77B | 4.13B | 4.36B | 4.76B | 5.17B |
| Retained earnings | -8.61B | -8.51B | -8.39B | -8.32B | -8.09B | -7.86B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -547.72M | -750.27M | -1.28B | -1.30B | -1.50B | -1.16B | -140.63M | 1.13B |
| Depreciation & amortization | 10.39M | 18.62M | 31.79M | 46.46M | 66.28M | 87.68M | 171.76M | 141.69M |
| Free cash flow | -688.55M | -908.88M | -1.51B | -1.61B | -1.97B | -1.75B | -669.77M | 861.05M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 1.63B | 0 | 4.23B | 3.44B | -- | -- | -- | -- |
| Ending cash balance | 740.71M | 620.78M | 1.39B | 4.38B | 3.88B | 3.19B | 2.64B | 4.61B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 44.08M | 263.60M | 402.55M | 417.35M | 201.34M | 462.82M |
| Depreciation & amortization | 32.80M | 35.61M | 37.28M | 35.98M | 41.14M | 40.52M |
| Free cash flow | -72.33M | 199.77M | 353.78M | 379.83M | 160.55M | 414.83M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 2.53B | 2.79B | 4.11B | 4.61B | 4.85B | 5.28B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -55.94 | -70.23 | -66.10 | -27.95 | -37.71 | -22.26 | -18.77 | 7.46 |
| ROA %i | -40.88 | -49.13 | -44.28 | -19.84 | -26.67 | -14.47 | -11.00 | 4.07 |
| ROIC %i | -48.61 | -59.72 | -56.32 | -24.86 | -33.63 | -18.67 | -15.37 | 5.65 |
| 5-year avg ROE %i | -- | -- | -61.32 | -48.16 | -52.14 | -45.40 | -35.11 | -20.17 |
| EBIT margin %i | -356.05 | -224.16 | -536.69 | -122.31 | -126.40 | -49.12 | -14.91 | 8.89 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 16.12 |
| Current ratioi | 7.89 | 3.78 | 4.61 | 4.76 | 3.55 | 2.32 | 1.80 | 3.41 |
| Quick ratioi | 7.44 | 3.42 | 4.40 | 4.45 | 3.22 | 1.97 | 1.51 | 2.97 |
| Debt / assetsi | 8.82 | 17.20 | 10.03 | 8.14 | 9.35 | 16.02 | 18.24 | 13.35 |
| LT debt / equityi | 10.91 | 27.70 | 5.51 | 4.00 | 5.56 | 6.22 | 6.32 | 23.27 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | 8.16 |
| Revenue CAGR (3Y) %i | 182.24 | 636.93 | 9.02 | 81.05 | 48.98 | 99.67 | 47.96 | 55.69 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -11.44 | -4.98 | 1.81 | 7.46 | 12.42 | 14.66 |
| ROA %i | -6.82 | -2.96 | 1.02 | 4.07 | 7.13 | 8.47 |
| ROIC %i | -9.46 | -4.31 | 1.09 | 5.65 | 9.84 | 11.99 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -7.08 | -2.21 | 3.67 | 8.89 | 12.88 | 16.05 |
| FCF / sales %i | -- | 3.61 | 9.33 | 16.12 | 19.06 | 21.36 |
| Current ratioi | 1.96 | 1.95 | 2.39 | 3.41 | 3.64 | 3.40 |
| Quick ratioi | 1.64 | 1.65 | 2.09 | 2.97 | 3.17 | 2.91 |
| Debt / assetsi | 17.06 | 16.28 | 13.36 | 13.35 | 13.43 | 12.46 |
| LT debt / equityi | 6.15 | 5.31 | 4.62 | 23.27 | 21.26 | 17.98 |
| Interest coveragei | -- | -- | -- | 8.16 | 8.79 | 8.49 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- BRUKINSA® is the largest reported line at 73.17% of revenue, across 8 reported segments.
- The next-largest line, TEVIMBRA®, is a distant second at 13.40% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
BRUKINSA®73.17%
TEVIMBRA®13.40%
XGEVA®6.13%
Other2.22%
BLINCYTO®2.14%
Other revenue1.48%
KYPROLIS®0.89%
POBEVCY®0.56%
Quote time 2026-10-08 05:10:03 · For reference only, not investment advice and not tailored to your situation.